FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4242040300> ?p ?o ?g. }

• W4242040300 endingPage "94" @default.
• W4242040300 startingPage "94" @default.
• W4242040300 abstract "94 Background: Pembrolizumab (pembro), an anti-PD-1 antibody, is approved for the treatment of patients (pts) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair (MMR) deficient colorectal cancer, both as first-line treatment and after progression following treatment with fluoropyrimidine, oxaliplatin, and irinotecan. The combination of lenvatinib, a multiple receptor tyrosine kinase inhibitor, and anti-PD-1 treatment showed synergistic antitumor activity in preclinical models. LEAP-005 (NCT03797326) is evaluating the efficacy and safety of lenvatinib plus pembro in pts with previously treated advanced solid tumors. We present findings from the colorectal cancer cohort. Methods: In this nonrandomized, open-label, phase 2 study, adult pts (aged ≥18 y) with histologically/cytologically documented metastatic and/or unresectable colorectal cancer, non–MSI-H/pMMR tumor per local determination, previous treatment with oxaliplatin and irinotecan in separate lines of therapy, measurable disease per RECIST v1.1, ECOG PS of 0‒1, and a tissue sample evaluable for PD-L1 expression were eligible. Pts received lenvatinib 20 mg QD plus pembro 200 mg Q3W for up to 35 cycles of pembro (~2 y) or until confirmed disease progression, unacceptable toxicity, or withdrawal of consent. Treatment with lenvatinib could continue beyond 2 y in pts with clinical benefit. Primary endpoints were ORR (per RECIST v1.1 by blinded independent central review) and safety. Secondary endpoints included disease control rate (DCR), duration of response (DOR), PFS, and OS. Tumor imaging was performed Q9W from treatment initiation for 54 wks, then Q12W to week 102, and Q24W thereafter. Results: 32 pts with colorectal cancer received treatment with lenvatinib plus pembro (median age, 56 y [range, 36-77]; male, 81%; 3L, 91%); median time from first dose to data cutoff (April 10, 2020) was 10.6 mos (range, 5.9-13.1) ORR was 22% (95% CI, 9-40; Table). Grade 3-5 treatment-related AEs occurred in 16 (50%) pts. Treatment-related AEs led to treatment discontinuation in 3 pts (grade 2 ischemic stroke [n = 1], grade 3 increased liver transaminases [n = 1], grade 5 intestinal perforation [n = 1]). Efficacy Results. Clinical trial information: NCT03797326. NR, not reached a Confirmation was not required for best overall response of SD, but a final visit response of SD or better must have occurred ≥6 wks after starting study treatment Conclusions: In pts with previously treated advanced non–MSI-H/pMMR colorectal cancer, lenvatinib plus pembro demonstrated promising antitumor activity and a manageable safety profile. Enrollment in the colorectal cohort was expanded to 100 pts. [Table: see text]" @default.
• W4242040300 created "2022-05-12" @default.
• W4242040300 creator A5002046745 @default.
• W4242040300 creator A5006472913 @default.
• W4242040300 creator A5016940852 @default.
• W4242040300 creator A5017654662 @default.
• W4242040300 creator A5017721654 @default.
• W4242040300 creator A5024527536 @default.
• W4242040300 creator A5028612075 @default.
• W4242040300 creator A5046110536 @default.
• W4242040300 creator A5049602816 @default.
• W4242040300 creator A5050098537 @default.
• W4242040300 creator A5053725787 @default.
• W4242040300 creator A5064237640 @default.
• W4242040300 creator A5069050806 @default.
• W4242040300 creator A5085658868 @default.
• W4242040300 creator A5090014532 @default.
• W4242040300 creator A5090832721 @default.
• W4242040300 date "2021-01-20" @default.
• W4242040300 modified "2023-10-16" @default.
• W4242040300 title "LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort." @default.
• W4242040300 doi "https://doi.org/10.1200/jco.2021.39.3_suppl.94" @default.
• W4242040300 hasPublicationYear "2021" @default.
• W4242040300 type Work @default.
• W4242040300 citedByCount "34" @default.
• W4242040300 countsByYear W42420403002021 @default.
• W4242040300 countsByYear W42420403002022 @default.
• W4242040300 countsByYear W42420403002023 @default.
• W4242040300 crossrefType "journal-article" @default.
• W4242040300 hasAuthorship W4242040300A5002046745 @default.
• W4242040300 hasAuthorship W4242040300A5006472913 @default.
• W4242040300 hasAuthorship W4242040300A5016940852 @default.
• W4242040300 hasAuthorship W4242040300A5017654662 @default.
• W4242040300 hasAuthorship W4242040300A5017721654 @default.
• W4242040300 hasAuthorship W4242040300A5024527536 @default.
• W4242040300 hasAuthorship W4242040300A5028612075 @default.
• W4242040300 hasAuthorship W4242040300A5046110536 @default.
• W4242040300 hasAuthorship W4242040300A5049602816 @default.
• W4242040300 hasAuthorship W4242040300A5050098537 @default.
• W4242040300 hasAuthorship W4242040300A5053725787 @default.
• W4242040300 hasAuthorship W4242040300A5064237640 @default.
• W4242040300 hasAuthorship W4242040300A5069050806 @default.
• W4242040300 hasAuthorship W4242040300A5085658868 @default.
• W4242040300 hasAuthorship W4242040300A5090014532 @default.
• W4242040300 hasAuthorship W4242040300A5090832721 @default.
• W4242040300 hasConcept C121608353 @default.
• W4242040300 hasConcept C126322002 @default.
• W4242040300 hasConcept C143998085 @default.
• W4242040300 hasConcept C203092338 @default.
• W4242040300 hasConcept C2776264508 @default.
• W4242040300 hasConcept C2777701055 @default.
• W4242040300 hasConcept C2779761222 @default.
• W4242040300 hasConcept C2779984678 @default.
• W4242040300 hasConcept C2780057760 @default.
• W4242040300 hasConcept C2780259306 @default.
• W4242040300 hasConcept C2780962732 @default.
• W4242040300 hasConcept C31760486 @default.
• W4242040300 hasConcept C526805850 @default.
• W4242040300 hasConcept C535046627 @default.
• W4242040300 hasConcept C71924100 @default.
• W4242040300 hasConceptScore W4242040300C121608353 @default.
• W4242040300 hasConceptScore W4242040300C126322002 @default.
• W4242040300 hasConceptScore W4242040300C143998085 @default.
• W4242040300 hasConceptScore W4242040300C203092338 @default.
• W4242040300 hasConceptScore W4242040300C2776264508 @default.
• W4242040300 hasConceptScore W4242040300C2777701055 @default.
• W4242040300 hasConceptScore W4242040300C2779761222 @default.
• W4242040300 hasConceptScore W4242040300C2779984678 @default.
• W4242040300 hasConceptScore W4242040300C2780057760 @default.
• W4242040300 hasConceptScore W4242040300C2780259306 @default.
• W4242040300 hasConceptScore W4242040300C2780962732 @default.
• W4242040300 hasConceptScore W4242040300C31760486 @default.
• W4242040300 hasConceptScore W4242040300C526805850 @default.
• W4242040300 hasConceptScore W4242040300C535046627 @default.
• W4242040300 hasConceptScore W4242040300C71924100 @default.
• W4242040300 hasIssue "3_suppl" @default.
• W4242040300 hasLocation W42420403001 @default.
• W4242040300 hasOpenAccess W4242040300 @default.
• W4242040300 hasPrimaryLocation W42420403001 @default.
• W4242040300 hasRelatedWork W1982756255 @default.
• W4242040300 hasRelatedWork W2039734044 @default.
• W4242040300 hasRelatedWork W2142100270 @default.
• W4242040300 hasRelatedWork W2379984063 @default.
• W4242040300 hasRelatedWork W3032174239 @default.
• W4242040300 hasRelatedWork W3172653328 @default.
• W4242040300 hasRelatedWork W3213507836 @default.
• W4242040300 hasRelatedWork W4212931506 @default.
• W4242040300 hasRelatedWork W4306377359 @default.
• W4242040300 hasRelatedWork W4318203757 @default.
• W4242040300 hasVolume "39" @default.
• W4242040300 isParatext "false" @default.
• W4242040300 isRetracted "false" @default.
• W4242040300 workType "article" @default.